Drugs / adipose tissue-derived stem/stromal cells
adipose tissue-derived stem/stromal cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03920397 | Mar 2015 → Mar 2021 | type 1 diabetes mellitus | Federal University of Rio de Janeiro | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adipose tissue-derived stem/stromal cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03920397 ↗ |
| Known as | adipose tissue-derived stromal/stem cells | “Adipose tissue-derived stromal/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patients.” PMID 33939911 ↗ Apr 2021 |
| Known as | ASCs | “The adipose tissue-derived stem/stromal cells (ASCs) that wil be extract on healthy volunteers will be isolate, culture and samples will be process at Core Cell Technology of...” NCT03920397 ↗ |
| Modality | Cell therapy | “A single dose of ASCs wil be infuse in a peripheral upper arm vein during 15-20 minutes.” NCT03920397 ↗ |
| Route | Intravenous | “A single dose of ASCs wil be infuse in a peripheral upper arm vein during 15-20 minutes.” NCT03920397 ↗ |